AstraZeneca

The Financial Times reported on Aug. 2 that Bristol-Myers Squibb and AstraZeneca are in discussions with regard to a possible merger. Astra shares fell 8% and Bristol shares were down about 1% in early trading on Aug. 3.

Why it matters: While smaller acquisitions are very common in biopharma, huge mergers have become much less common. If this deal went through, it would be the biggest in history. With market caps around $260 billion for Astra and $130 billion for Bristol, Astra would be the likely "acquirer" in this deal. The combined company would likely only trail Eli Lilly, Johnson & Johnson, and AbbVie in size. Possible motivators could be complementary timing of patent cliffs, access to specific pipeline programs, and geographic diversification, although the drain from integrating businesses and potential Federal Trade Commission concerns due to the mutual oncology focus are real issues here.

The bottom line: We're not making any changes to our fair value estimates for these wide-moat names ($184/GBX 13,500 for Astra and $70 for Bristol), although we could be somewhat cautious if these plans came to fruition. With Bristol trading near its fair value estimate, we think there is little room for execution missteps. The discussions lead us to wonder if Astra's confidence in its ability to reach $80 billion in revenue by 2030 is faltering (we model $71 billion) and if Bristol is concerned about the risks surrounding its own key pipeline assets like milvexian, Cobenfy, and next-generation oral multiple myeloma therapies. That said, Bristol's massive 2028 patent cliff could fit well with Astra's more limited patent exposure, and Astra could gain access to Bristol/BioNTech's PD-L1/VEGF bispecific pumitamig as well as increased exposure to the US market.

BLANK PAGEBristol saw 69% of revenue from US branded drugs in 2025, as compared to only 42% at Astra. Most Favored Nation pricing for pipeline drugs as part of individual agreements between the Trump Administration and large-cap biopharmas like Astra and Bristol could mean higher international launch prices for some therapies in international markets (to raise the comparator price that determines US pricing), or it could mean that certain international markets are foregone altogether, creating uncertainty in these cash flows.

For more information on the portfolios and pipelines at these two firms, please see our recent in-depth report, "Biopharma Product Pipelines Rise to Meet Steeper Patent Cliffs."

We maintain our fair value estimate of $184 per ordinary share. Overall, Astra looks well positioned for low- to mid-single-digit growth for at least the next five years due to the strength of its in-line drugs and late-stage pipeline. We view the company as especially strong in oncology.

We expect Tagrisso (lung cancer with EGFR driver mutations) to enjoy peak sales of $8 billion by around 2030 before declining afterward. Other key drugs in the middle of their lifecycle include Calquence (blood cancers), Imfinzi (various cancers), and Ultomiris (complement-mediated autoimmune diseases). For its respiratory franchise, we expect steady revenue, with growth in Breztri and Tezspire offsetting declines in Symbicort.

We have strong growth expectations for recently launched drugs Enhertu (HER2-expressing cancers, especially breast cancer), Truqap (HR-positive breast cancers), and Wainua (transthyretin amyloidosis, a rare disease), as well as several pipeline drugs, including camizestrant (ER-positive breast cancer) and baxdrostat (uncontrolled or treatment-resistant hypertension), which could be approved in the second half of 2026.

Additionally, Astra has a large slate of pivotal data readouts over the next few years, including phase 3 trials for oncology drugs Datroway and camizestrant and cardiometabolic drugs laroprovstat (oral PCSK9 inhibitor for high cholesterol) and elecoglipron (oral GLP-1 receptor agonist for obesity and diabetes).

We expect that these growth drivers can more than offset declines in older drugs, including Farxiga (cardiometabolic drug) and Tagrisso. We forecast revenue declines to begin in 2026 for Farxiga and 2032 for Tagrisso.

We estimate a cost of capital of 7.1%, consistent with those of pharmaceutical peers.

Patents, economies of scale, and a powerful distribution network support AstraZeneca’s wide moat. Despite a relatively late emergence from the industry patent cliff that largely started in 2012, Astra's strong lineup of next-generation drugs should significantly offset sales lost to new generic competition. Further, we project that the majority of new drug sales will be supported in therapeutic areas with strong pricing power, with a heavy focus on differentiated oncology drugs such as Tagrisso, Imfinzi, Enhertu, and Calquence. The majority of the firm's pipeline focuses on differentiated drugs in critical-care markets, with the exception of the company's small-molecule respiratory pipeline, which looks less differentiated and likely to face pricing pressures in an area where payers have viewed slightly improved follow-on drugs as largely interchangeable with older medicines.

Astra's patent-protected drugs carry strong pricing power, which enables the firm to generate returns on invested capital in excess of its cost of capital. The patents also give the company time to develop the next generation of drugs before generic competition arises. Additionally, Astra holds a diversified product portfolio, with less dependence on any single drug. Its most significant loss of exclusivity events are generics competition for cardiometabolic drug Farxiga (which began in 2026), Lynparza (expected in 2027-28), and Tagrisso (expected after 2032 for major markets). Astra’s operating structure enables cost-cutting measures following patent losses, thereby reducing margin pressure from lost high-margin drug sales. Overall, Astra's established product line creates the enormous cash flows needed to fund the average $800 million in development costs per new drug. In addition, the firm's powerful distribution network sets up the firm as a strong partner for smaller drug companies that lack Astra's resources.

We think the firm does face environmental, social, and governance risks, particularly related to potential US drug price-related policy reform (close to one-third of sales are generated in the US) that could increase access by lowering drug prices. Ongoing product governance issues (including litigation related to side effects and patents) also weigh on the firm. While we have factored these threats into our analysis, we don't see them as material to our moat rating for AstraZeneca.

The company has a healthy oncology portfolio, including Tagrisso, Imfinzi, Calquence, Enhertu, and Truqap, which looks well positioned to drive major cash flows over the next decade.

The management team is focusing the pipeline toward areas of high unmet medical need, which should increase the odds of success and bring strong pricing power for the new drugs.

AstraZeneca has a large presence in emerging markets and should benefit from these markets' fast growth prospects.

The company's strong entrenchment in respiratory disease could cause challenges, as pricing power in this market tends to be weak.

Astra holds some litigation risk with several historical drugs focused in chronic care areas that may eventually spark legal concerns around long-term side effects.

Emerging EGFR drugs could pose a major threat to Astra’s high-selling drug Tagrisso if the new drugs are priced lower or have better clinical data.